$NUOX · NuvOx Therapeutics, Inc.
NuvOx Therapeutics, a clinical-stage biopharmaceutical company, filed Amendment No. 1 to its S-1 registration statement for an IPO of 2,860,000 shares at an estimated price range of $6.00 to $8.00 per share, targeting gross proceeds of approximately $17.2 million to $22.9 million. The company intends to list on NYSE American under the symbol "NUOX." Proceeds will fund completion of ongoing Phase IIb trials in GBM and stroke, a planned Phase II ARDS trial, and preparation for a pivotal Phase III GBM trial.
- Proposed IPO of 2,860,000 shares at $6.00–$8.00 per share, targeting $17.2M–$22.9M in gross proceeds.
- NanO₂ is a clinical-stage oxygen therapeutic targeting acute ischemic stroke, GBM, ARDS, and sickle cell anemia.
- Phase IIb GBM trial fully enrolled at 93 patients; Phase IIb UK stroke trial has treated 23 of 150 planned subjects.
- NanO₂ holds FDA orphan drug designation for GBM (2015) and sickle cell anemia (2016).
- No public market exists; listing is contingent on NYSE American approval under symbol NUOX.
Price data unavailable.
A pre-revenue biotech with no approved products is asking public investors to fund late-stage hypoxia trials in indications where multiple prior therapies have failed.
NuvOx enters a crowded biotech IPO market targeting hypoxia-related indications where multiple neuroprotective stroke agents have failed prior trials. No pharmaceutical treatments are approved for hypoxia in acute ischemic stroke, GBM, or ARDS — a high-risk, high-reward whitespace.
The company has no approved products, has incurred losses since inception, and its lead candidate NanO₂ has only completed small Phase Ib/IIa trials. SAEs including radiation necrosis, motor dysfunction, and platelet count decrease were deemed possibly/probably related to NanO₂. The ongoing Phase II
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.